Walgreens acquires Carle Foundation
CHICAGO — Walgreens has acquired the 10-site retail pharmacy chain Carle Foundation, a pharmacy operator out of the Urbana-Champaign, Ill., area with the majority of stores located inside medical office buildings, according to Dresner Partners, which brokered the deal.
"Carle’s overarching objective was to continue providing high-quality pharmacy services to the Urbana-Champaign community, particularly the large patient base of Carle’s multispecialty physician practice,” stated Carle’s COO John Snyder. “This transaction accomplishes that goal, and creates new opportunities for Carle."
"This transaction is an example of an accelerating trend in the hospital industry,” noted Ejaz Elahi, director of Dresner Partners’ Healthcare Practice. “As hospitals review their clinical service portfolios and financial condition in the face of regulatory and reimbursement challenges, they are compelled to seek new ways to develop the most clinically effective and cost-efficient delivery systems possible. In the case of Carle, the sale of Rx will enable Carle to focus more closely on its core business while entrusting the provision of pharmacy services to a highly reputable operator."
Walgreens currently operates about 100 hospital-based pharmacies.
Bartell Drugs selects KSS Retail for price, promotion optimization
CINCINNATI — Seattle-based retail pharmacy chain Bartell Drugs will use KSS Retail’s price modeling and optimization services to better understand its customers’ wants and needs and to provide value for its shoppers, KSS Retail said Monday.
“Our customers count on us for great service and value,” Bartell SVP merchandising Ron Miller stated. “We chose KSS Retail because we know price optimization will allow us to better understand what’s important to our shoppers, which will help us deliver the value they’ve come to expect.”
KSS Retail is part of Dunnhumby, a British retail data-analysis company, and also has worked with Kroger, Bi-Lo, United Supermarkets, 7 Eleven and others.
Amneal launches three generic liquid drugs
BRIDGEWATER, N.J. — Generic drug maker Amneal has launched three new liquid drugs, the company said Monday.
Amneal announced the launch of risperidone oral solution, a generic version of Johnson & Johnson’s schizophrenia and bipolar disorder treatment Risperdal, in the 1-mg/mL strength; ondansetron oral solution, a generic version of GlaxoSmithKline’s Zofran used to prevent nausea and vomiting associated with cancer treatment and postoperative recovery, in the 4-mg/5-mL strength; and levetiracetam oral solution, a generic version of UCB Pharma’s epilepsy drug Keppra, in the 100-mg/mL strength. The generic versions of Zofran and Keppra are respectively available in strawberry-scented and grape-flavored liquids.
“Since Amneal’s acquisition of its Branchburg, N.J., liquids plant a few years ago, we have committed significant [research and development] resources to developing a powerful product pipeline in the liquid, nasal spray and topical dosage forms that are now beginning to come to market,” Amneal president Chirag Patel said in a statement. “And the most exciting products are still to come, enhancing an already strong pipeline.”